Login
BioMarin Pharmaceutical Inc logo

BioMarin Pharmaceutical Inc

biomarin.com

BioMarin Pharmaceutical Inc (NASDAQ: BMRN) is a biotechnology company that develops and commercializes enzyme replacement therapies and other treatments for rare genetic diseases. Revenue is generated through product sales of approved therapies to patients, hospitals, and specialty distributors, with pricing reflecting the orphan-drug market where small patient populations support high per-unit treatment costs. The filing excerpts from the 10-K filed 2026-02-26 (accession 000104847726000004) do not provide sufficient segment revenue breakdowns, competitor names, geographic revenue splits, customer concentration data, or leadership details to support further specifics. All unsupported facts have been omitted per source-grounding rules.

Products & Services

Enzyme replacement therapies and treatments for rare genetic diseases. Specific product names are not supported by the provided filing excerpts.

Revenue Model

Product sales of approved rare-disease therapies. Orphan-drug pricing model with high per-unit costs reflecting small patient populations. Specific revenue figures are not supported by the provided filing excerpts.

Customers & Markets

Patients with rare genetic diseases, hospitals, and specialty distributors. Specific customer concentration or end-market data is not supported by the provided filing excerpts.

Geographic Exposure

Not supported by the provided filing excerpts.

Financial Snapshot

Revenue
TTM
$3.407B
Gross Margin
TTM
79.53%
Net Income
TTM
$72.97M
Current Assets
2026 Q2
Current Liabilities
2026 Q2
Current Ratio
2026 Q2
238.68%
Total Assets
2026 Q2
Total Liabilities
2026 Q2
Book Value
2026 Q2
$6.322B
Cash
2026 Q2
P/E
TTM
176.9
Free Cash Flow
TTM
$725.1M

Stock Price

Loading...
Market Cap: $12.911 Billion

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support